ES2156602T3 - Expresion de albumina en levaduras. - Google Patents

Expresion de albumina en levaduras.

Info

Publication number
ES2156602T3
ES2156602T3 ES95921063T ES95921063T ES2156602T3 ES 2156602 T3 ES2156602 T3 ES 2156602T3 ES 95921063 T ES95921063 T ES 95921063T ES 95921063 T ES95921063 T ES 95921063T ES 2156602 T3 ES2156602 T3 ES 2156602T3
Authority
ES
Spain
Prior art keywords
pct
albumina
leaves
expression
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921063T
Other languages
English (en)
Inventor
Patricia Carol Wood
Alan Victor Quirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Application granted granted Critical
Publication of ES2156602T3 publication Critical patent/ES2156602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA REDUCCION (PREFERIBLEMENTE LA ELIMINACION) DE LA PROTEINA HSP150, EN UNA LEVADURA UTILIZADA PARA PRODUCIR PROTEINAS FORANEAS DESEADAS, ESPECIALMENTE ALBUMINA HUMANA, FACILITA LA PURIFICACION POSTERIOR DE DICHA PROTEINA.
ES95921063T 1994-06-07 1995-06-07 Expresion de albumina en levaduras. Expired - Lifetime ES2156602T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9411356A GB9411356D0 (en) 1994-06-07 1994-06-07 Yeast strains

Publications (1)

Publication Number Publication Date
ES2156602T3 true ES2156602T3 (es) 2001-07-01

Family

ID=10756304

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921063T Expired - Lifetime ES2156602T3 (es) 1994-06-07 1995-06-07 Expresion de albumina en levaduras.

Country Status (14)

Country Link
US (1) US5783423A (es)
EP (1) EP0764209B1 (es)
JP (1) JP3667339B2 (es)
KR (1) KR100380532B1 (es)
AT (1) ATE198624T1 (es)
AU (1) AU698319B2 (es)
CA (1) CA2190373C (es)
DE (1) DE69519856T2 (es)
DK (1) DK0764209T3 (es)
ES (1) ES2156602T3 (es)
GB (2) GB9411356D0 (es)
GR (1) GR3035568T3 (es)
PT (1) PT764209E (es)
WO (1) WO1995033833A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6274305B1 (en) 1996-12-19 2001-08-14 Tufts University Inhibiting proliferation of cancer cells
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US6258559B1 (en) * 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
EP1183385B1 (en) 1999-05-21 2006-07-19 Cargill Dow LLC Methods and materials for the synthesis of organic products
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1363992A1 (en) * 2001-02-26 2003-11-26 DSM IP Assets B.V. Method for increasing the intracellular glutamate concentration in yeast
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
EP1391510B1 (en) 2001-05-29 2007-09-12 Asahi Glass Company Ltd. Method of constructing host and process for producing foreign protein
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0224082D0 (en) * 2002-10-16 2002-11-27 Celltech R&D Ltd Biological products
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329681D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
EP2330200B1 (en) 2004-12-23 2017-04-05 Albumedix A/S Gene expression technique
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
EP2594583A1 (en) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Transferrin variants and conugates
US20110294988A1 (en) 2009-02-06 2011-12-01 Novozymes Bio Pharma DK A/S Purification Process
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
WO2014138371A1 (en) 2013-03-06 2014-09-12 Glaxosmithkline Llc Host cells and methods of use
CA2919327C (en) 2013-08-09 2022-06-21 Novozymes A/S Reducing content of hexenuronic acids in cellulosic pulp
US12629445B2 (en) 2020-03-20 2026-05-19 Bard Peripheral Vascular, Inc. Reactive hydrogel forming formulations and related methods, including methods of preparation
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
WO2022146917A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Also Published As

Publication number Publication date
JPH10501123A (ja) 1998-02-03
US5783423A (en) 1998-07-21
GB2302329B (en) 1998-04-29
WO1995033833A1 (en) 1995-12-14
DE69519856T2 (de) 2001-07-19
KR100380532B1 (ko) 2004-03-24
EP0764209A1 (en) 1997-03-26
PT764209E (pt) 2001-05-31
ATE198624T1 (de) 2001-01-15
DE69519856D1 (de) 2001-02-15
CA2190373C (en) 2003-01-07
GB9411356D0 (en) 1994-07-27
CA2190373A1 (en) 1995-12-14
JP3667339B2 (ja) 2005-07-06
GB2302329A (en) 1997-01-15
AU698319B2 (en) 1998-10-29
GR3035568T3 (en) 2001-06-29
AU2626295A (en) 1996-01-04
DK0764209T3 (da) 2001-03-19
EP0764209B1 (en) 2001-01-10
GB9622229D0 (en) 1996-12-18

Similar Documents

Publication Publication Date Title
DK0764209T3 (da) Albuminekspression i gær
ATE180261T1 (de) Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
PT749478E (pt) Estirpes de levedura e albuminas modificadas
GR3033850T3 (en) Chloropyrimide intermediates
DE69131699D1 (de) Verändertes menschliches iL-6
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
ATE190068T1 (de) Neue hil-4-mutantenproteine als antagonisten oder partielle agonisten des humanen interleukin 4
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
MX9602570A (es) Metodos y materiales anti-fungosos.
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
MX9700244A (es) Utilizacion de un poliholosido en una composicion limpiadora o desmaquillante, y composicion que lo incluye.
AU1828388A (en) Promoters for the expression of foreign dna in methylotrophic bacteria, the obtaining thereof and the use thereof
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
AU637589B2 (en) Ancrod proteins, their production and use
GR930300003T1 (en) Inhibitor of proliferation of endothelial cells.
DE69323191D1 (de) Wasserlösliche retinoide
BR9611904A (pt) Dioxidos de ditiazol
ES2191785T3 (es) Proteina de accion antitumoral.
ATE315583T1 (de) Analoge des thymosin alpha 1
AU7614798A (en) High level expression, purification and refolding of the Neisseria meningitidis outer membrane group B porin proteins
ATE235260T1 (de) Verfahren zum herstellen von nebenwirkungsfreien konstrastmitteln bei ultrafiltration

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 764209

Country of ref document: ES